24 April 2021, Expert meeting : In this second of a two-part series by Professors Maura Pugliatti and Carlo Pozzilli, They expand on their earlier presentation (Risk in Multiple Sclerosis Treatment) to guide you in how to manage and mitigate risks associated with treating MS patients.
No two MS patients are the same, and yet only a limited number of disease-modifying therapies are available for MS neurologists to treat their patients. In this second of a two-part series, Professors Maura Pugliatti and Carlo Pozzilli expand on their earlier presentation (Risk in Multiple Sclerosis Treatment) to guide you in how to manage and mitigate risks associated with treating MS patients. They follow a multifaceted approach based on their own experience and literature reports to provide a set of key messages underlying risk mitigation in MS treatment.
Maura PUGLIATTI, MD, PhD is Full Professor of Neurology at the University of Ferrara, Director of the University Hospital Unit of Clinical Neurology, S. Anna Hospital, Ferrara, Italy. She is also Director of the Residency School of Neurology at the same University. In 2007 she took a PhD and in 2007-10 was Research Fellow at the Dept. of Public Health and Primary Health Care, University of Bergen, Norway, actively coordinating a large multi-center case-control study on multiple sclerosis and environmental risk factors. Since 2011 she is Adjunct Professor at the Dept. of Clinical Medicine, McGill University, Montreal, Canada within collaborative research in MS epidemiology. She has been Visiting Professor at the University of Bergen (Erasmus Teaching Staff Mobility program to medical students, 2010-12), University of Belgrade, Serbia (to PhD student, 2015), and has been a faculty member of the PhD School in at the University of Medicine and Pharmacy, Cluj Napoca, Romania, since 2016. In 2008-14 she was Chair of the EFNS Scientist Panel of Neuroepidemiology and Public Health, and has co-chaired the same Panel for the European Academy of Neurology in 2015-18. She is a member of ParadigMS Foundation founders.
Her main research areas are multiple sclerosis, epidemiology of amyotrophic lateral sclerosis, through collaborative research at national and international level. She is author of 137 papers in peer-reviewed scientific journals, has a total impact factor > 500 and H-index=37.
Professor Pozzilli studied at the University of Rome “La Sapienza”. He then moved to the Hammersmith Hospital in London, UK, to take up a research post in 1980.In 1983, he became a Board Certified Neurologist at the University of Rome. In 1986 obtained a research grant in Neuroimaging at the Tohoku University, Sendai Japan.In 1987, he was awarded a PhD in Clinical Neurosciences by the University of Rome, where he became Full Professor in 2006. In 2002 he funded and become Director of the Multiple Sclerosis (MS) Center of OspedaleS.Andrea, University of Rome which is his actual position.
Professor Pozzilli’s fields of interest include the clinical aspects and treatment of MS; he has published more than 350 papers and reviews on these subjects.
Professor Pozzilli is a member of several National and International Societies.
He has participated as a first investigator in at least 250 multicentre clinical trials on patients with MS. He was also member of the Steering Committee and Advisory Board inseveral multicentre trials.
Minimum two MS experts collaborate to produce an educational slide deck. These slide decks are presented (live) to ParadigMS members, peer reviewed and updated.
The slide decks are published on the ParadigMS website “on behalf of ParadigMS”.
Based on the slide decks, publications are produced. These publications are peer reviewed and published as consensus publications.
Regional (fe: Scandinavian countries, Benelux, …) or national events where state-of-the-art science is transferred to general neurologists and other care givers (nurses, etc) that are confronted with MS in their day to day practice.
Webinars can complement the educational events.
The educational slide decks, events and webinars can be important building blocks of accredited educational programs.